Cancer glossary
pCR after neoadjuvant therapy: what ypT0 ypN0 means on pathology
pCR means no invasive cancer was found in tissue removed after neoadjuvant therapy. How it is written (ypT0/is ypN0, RCB-0) and what it means for the outlook.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026
In short
Pathologic complete response (pCR) means that after neoadjuvant therapy the pathologist finds no invasive cancer in the removed tissue or in the removed lymph nodes. It is assessed under the microscope, not on scans, and only on the surgical specimen.
How it appears in your report
- “ypT0 ypN0” — no invasive or non-invasive cancer in the organ or lymph nodes.
- “ypTis ypN0” — no invasive cancer, only carcinoma in situ left; under the FDA definition this also counts as pCR.
- “RCB-0” — the Residual Cancer Burden system; class zero corresponds to pCR.
- In Russian-language reports you may see “complete treatment-related pathomorphosis” or “grade IV pathomorphosis”, which describe complete disappearance of tumor cells.
The prefix “y” means the stage is assessed after treatment; more on the page pTNM and ypTNM.
What it means
| Finding | pCR or not |
|---|---|
| ypT0 ypN0 | Yes, under any definition |
| ypTis ypN0 | Yes, under one of the two FDA definitions (in situ allowed) |
| ypN0(i+) — isolated tumor cells in a node | No |
| Tumor emboli in vessels with no tumor in the tissue | No, under AJCC 8th edition |
| RCB-I, II, III | No, residual tumor present |
In the pooled CTNeoBC analysis (about 12,000 patients, 12 trials), pCR in breast cancer was linked to better event-free and overall survival. The link was strongest in triple-negative and HER2-positive, hormone receptor-negative cancer. Yet the authors could not validate pCR as a substitute for survival when comparing drugs.
Does it affect treatment
Yes, often. In breast cancer, whether tumor remains after neoadjuvant therapy is taken into account when choosing treatment after surgery. pCR is a good prognostic sign, but not a reason to skip follow-up. The specific plan is approved by your treating doctor or a tumor board. If you want help understanding your post-surgery report, I can review it in a consultation.
Questions to ask your doctor
- Do I have a pCR by the ypT0/is ypN0 definition? If not, what is my RCB class?
- How does the result change the plan after surgery?
- What follow-up schedule do I need?
Sources
- Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval — U.S. FDA, 2020
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis — Cortazar P. et al., The Lancet, 2014 (summary in The ASCO Post)
- Патоморфологическая оценка операционного материала у пациентов с диагнозом рак молочной железы после неоадъювантной терапии — N.N. Petrov National Medical Research Center of Oncology, 2023 (in Russian)
- Лечебный патоморфоз злокачественных опухолей: клинические и морфологические критерии — Lisaeva A.A. et al., ABV-press, 2011 (in Russian)
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
